BACKMethods to redirect therapeutic immune cells to the bone marrow and uses thereof
[Licensing negotiation in progress]
[Invitation for Expression of Interest- Deadline: 24 December 2025]
We are inviting expressions of interest (EoI) for commercializing “Methods to redirect therapeutic immune cells to the bone marrow and uses thereof” technology. The innovation is developed by Professor LEUNG Kam Tong, Professor of Department of Paediatrics of The Chinese University of Hong Kong (CUHK Reference: 25/MED/1531).
The Technology
The invention provides a method to improve cell therapy. In particular, the invention provides therapeutic compositions of CAR T cells with improved bone marrow homing properties, and methods of making the therapeutic compositions involving contacting CAR T cells with specific chemicals for a period of time. The invention further provides methods of improving CAR T cell therapy involving infusing the therapeutic composition to subjects in need.
Commercialization
The technology is now available for licensing on an exclusive basis. In order to fully realize the benefit of the technology, we expect substantial investment is necessary to enable further research and development. In addition to the financial commitment, the licensee is expected to have the appropriate expertise as well as plans in marketing and strategizing the end product to ensure successful transfer of the technology to the society. Previous or existing business involvement and experience in this area is a plus.
This invitation of expression of interest is without prejudice. We also stress that this invitation is not a tender, and the University is not bound to accept any offer, or to accept the highest monetary offer, as there are additional considerations (such as the widest possible benefit to the community) that we, as a public institution, will need to take into consideration.
Methods to redirect therapeutic immune cells to the bone marrow and uses thereof
[Licensing negotiation in progress]
[Invitation for Expression of Interest- Deadline: 24 December 2025]
We are inviting expressions of interest (EoI) for commercializing “Methods to redirect therapeutic immune cells to the bone marrow and uses thereof” technology. The innovation is developed by Professor LEUNG Kam Tong, Professor of Department of Paediatrics of The Chinese University of Hong Kong (CUHK Reference: 25/MED/1531).
The Technology
The invention provides a method to improve cell therapy. In particular, the invention provides therapeutic compositions of CAR T cells with improved bone marrow homing properties, and methods of making the therapeutic compositions involving contacting CAR T cells with specific chemicals for a period of time. The invention further provides methods of improving CAR T cell therapy involving infusing the therapeutic composition to subjects in need.
Commercialization
The technology is now available for licensing on an exclusive basis. In order to fully realize the benefit of the technology, we expect substantial investment is necessary to enable further research and development. In addition to the financial commitment, the licensee is expected to have the appropriate expertise as well as plans in marketing and strategizing the end product to ensure successful transfer of the technology to the society. Previous or existing business involvement and experience in this area is a plus.
This invitation of expression of interest is without prejudice. We also stress that this invitation is not a tender, and the University is not bound to accept any offer, or to accept the highest monetary offer, as there are additional considerations (such as the widest possible benefit to the community) that we, as a public institution, will need to take into consideration.
N/A
Mr. Paul Cheung
Knowledge Transfer Office
Professor LEUNG Kam Tong
N/A